Drug Type Small molecule drug |
Synonyms N-(3-(2-cyanopropan-2-yl)-5-(4-methyl-1H-imidazol-1-yl)phenyl)-2-fluoro-4-methyl-5-((8-((1-methyl-1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)benzamide dihydrochloride, KF 1601, KF-1601 + [1] |
Mechanism ABL1 inhibitors(ABL proto-oncogene 1 inhibitors), Bcr-Abl T315I inhibitors(BCR-ABL T315I mutation inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Immunoforge Co. Ltd.Startup |
Active Organization Immunoforge Co. Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Philadelphia chromosome positive chronic myelogenous leukemia | Preclinical | US | Immunoforge Co. Ltd.Startup | 12 Jan 2023 |